ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY KHÁNG TKI: CA LÂM SÀNG THỰC TIỄN TẠI BỆNH VIỆN TRUYỀN MÁU HUYẾT HỌC THÀNH PHỐ HỒ CHÍ MINH VÀ Y VĂN
Background: We describe the characteristics, management, and clinical outcomes of patients with chronic myeloid leukemia (CML) who exhibit resistance to tyrosine kinase inhibitors (TKIs).Case presentation: We report two cases of imatinib-resistant CML, detailing their management and follow-up to the present. Information regarding diagnosis, clinical features, treatment history, and assessments before and after switching TKI therapies was recorded and described. Among the two imatinib-resistant CML patients, the first patient was switched to dasatinib and subsequently to ponatinib; the patient currently maintains a complete cytogenetic response (CCyR). The second patient, who has not undergone hematopoietic stem cell transplantation (no suitable matched related donor was available and haploidentical transplantation was not approved at consultation), is currently being treated with nilotinib and has achieved a major molecular response (MMR). The cis/trans configuration of the detected mutations was not determined.Conclusion: Managing TKI-resistant CML remains a challenge. The selection of subsequent TKI therapy must be tailored based on mutational analysis results, clinical history, patient status, and specific therapeutic goals.
Authors
- Thị Minh Nhật Dương
- Vũ Hà Thanh Lê
- Thị Hương Giang Nguyễn
Publication Details
- Journal
- Journal of Clinical Medicine Bach Mai Hospital
- Published
- 2026-11-21
- DOI
- https://doi.org/10.52322/jocmbmh.156.0304
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00